Creating a virtual startup is an option for a seasoned pharma scientist who wants to develop drugs on a lean budget. In the past this has only been feasible when going after a known target. Now, however, improved CRO capabilities in biology make it possible to launch a company that explores the science of a pathway while simultaneously developing drugs to target that pathway. A prime example of such a company is Vivace Therapeutics, co-founded and led by Sofie Qiao. Interested in hearing Vivace's story? Join us on February 7.
Where & When
Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Noon to 1:00 PM, Thursday, February 7
About the Speaker
Dr. Qiao is the founding president and CEO of Vivace Therapeutics, and a member of the board of directors. Prior to co-founding Vivace, she served as managing director of WuXi ventures, the corporate venture arm of WuXi AppTec. Dr. Qiao co-founded the chemistry-driven drug discovery company LEAD Therapeutics in 2006, assembled the management team and played a central role in raising $17 million in Series A financing. The company was acquired in 2010 by BioMarin for up to $97 million, primarily for its PARP inhibitor (Talazoparib), then in preclinical development. Dr. Qiao began her industry career at Genzyme as a medicinal chemist, and later moved into business roles with McKinsey & Company, Syrrx (now Takeda California) and Discovery Partners International (now Galapagos). She holds a doctorate in organic chemistry from Massachusetts Institute of Technology and an A.B. in chemistry from Harvard University.